IRLAB Therapeutics AB (FRA:6IRA) Buyback Yield % : 0.00 (As of Apr. 14, 2025)

View and export this data going back to 2020. Start your Free Trial

What is IRLAB Therapeutics AB Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

IRLAB Therapeutics AB's current buyback yield was 0.00%.

IRLAB Therapeutics AB Buyback Yield % Historical Data

The historical data trend for IRLAB Therapeutics AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Buyback Yield % Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

0.01

IRLAB Therapeutics AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IRLAB Therapeutics AB's Buyback Yield %

For the Biotechnology subindustry, IRLAB Therapeutics AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

IRLAB Therapeutics AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

IRLAB Therapeutics AB's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	48.029768
	=	0.00%

IRLAB Therapeutics AB's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	0)		/	48.029768
	=	0.00%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

IRLAB Therapeutics AB Buyback Yield % Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (FRA:6IRA) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

IRLAB A:Sweden

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines